Gilead Sciences, Inc.
$166.43-$0.10 (-0.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $160.4B
- P/E
- 18.8x
- EV / EBITDA
- 12.9x
- Revenue
- $29.4B
- Net margin
- 28.9%
- ROCE
- 22.7%
Price chart
Technical chartScreen technicals →+33.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +6.3%
- 3M
- +16.0%
- 6M
- +27.3%
- 1Y
- +33.2%
- 5Y
- +142.3%
52-week range
Day change -$0.10 (-0.1%) from $167 to $166 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in GILD, bought on each weekday since 2021.
News & filings
What Gilead Sciences filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity of 37.5% against a peer median of 12.5%.
Concerns (1)
- Revenue grew 2.6% a year over three years.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Read moreShow less
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Shares outstanding
- 1.24B
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $160.4B
- P/E
- 18.8x
- P/B
- 7.1x
- EV / EBITDA
- 12.9x
- EV / Sales
- 6.0x
- P/S
- 5.4x
- 52-week high
- $174.48
- 52-week low
- $118.30
Profitability
- Operating margin
- 39.7%
- Net margin
- 28.9%
- EBITDA margin
- 46.1%
- ROE
- 37.5%
- ROCE
- 22.7%
- ROA
- 14.4%
- Asset turnover
- 0.50
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $29.4B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 2.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 2.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1672.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $9.5B
Solvency
- Current ratio
- 1.55
- Debt / Equity
- 1.10
- Debt / Assets
- 0.42
- CFO / Net profit
- 1.18
- Cash / Market cap
- 6.0%
Where the revenue went
Of every $100 of FY2025 revenue, $29 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $6.2B |
| Revenue | Gross profit | $23.2B |
| Gross profit | Research and development | $5.8B |
| Gross profit | Selling, general and administrative | $5.7B |
| Gross profit | Operating income | $11.7B |
| Operating income | Pretax income | $9.8B |
| Operating income | Interest and other expense | $1.9B |
| Pretax income | Tax and other | $1.3B |
| Pretax income | Net income | $8.5B |
Revenue and net profit
Revenue grew 2.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $27.3B | $4.6B |
| FY2023 | $27.1B | $5.7B |
| FY2024 | $28.8B | $480.0M |
| FY2025 | $29.4B | $8.5B |
Cash flows
FY2025: $10.0B from operations, $9.5B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $9.1B | $8.3B |
| FY2023 | $8.0B | $7.4B |
| FY2024 | $10.8B | $10.3B |
| FY2025 | $10.0B | $9.5B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $29.4B+2.4%1Y
- EBITDA
- $13.6B+206.3%1Y
- Net profit
- $8.5B+1,672.9%1Y
- Cash from operations
- $10.0B-7.5%1Y
- Free cash flow
- $9.5B-8.2%1Y
- Revenue CAGR, 3Y
- 2.6%
- Net profit CAGR, 3Y
- 22.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $29.4B | $13.6B | $8.5B | $9.5B | 37.5% | +2.4% | +1672.9% |
Monthly returns
Month-by-month returns of GILD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $59.0B |
| Current assets | $18.3B |
| Non-current assets | $40.7B |
| Liabilities | $36.4B |
| Current liabilities | $11.8B |
| Non-current liabilities | $24.6B |
| Equity | $22.6B |
| Paid-in capital | $8.9B |
| Retained earnings | $13.7B |
| Minority interest | -$84.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; GILD highlighted.
P/E against peers
GILD trades at 18.8x earnings against a peer median of 25.5x (a 26% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Gilead Sciences, Inc.GILDthis companyP/E ↓ discount | $160.4B | 18.8x | 7.1x | 37.5% | 12.9x |
| Amgen Inc.AMGN | $186.5B | 24.2x | 21.5x | 89.1% | 13.7x |
| Thermo Fisher Scientific Inc.TMO | $179.1B | 26.7x | 3.4x | 12.6% | 18.1x |
| Abbott LaboratoriesABT | $158.1B | 24.2x | 3.0x | 12.5% | 13.5x |
| Intuitive Surgical, Inc.ISRG | $148.3B | 51.9x | 8.3x | 16.0% | 39.3x |
| Pfizer Inc.PFE | $146.4B | 18.8x | 1.7x | 9.0% | 12.5x |
| Danaher CorporationDHR | $132.1B | 36.6x | 2.5x | 6.9% | 21.2x |
| CVS Health CorporationCVS | $121.0B | 68.4x | 1.6x | 2.4% | 19.5x |
| Bristol-Myers Squibb CompanyBMY | $115.6B | 16.4x | 6.3x | 38.2% | 10.0x |
| Peer median | — | 25.5x | 3.2x | 12.5% | 15.9x |
Year-to-date ROI
GILD since 1 January, against earlier years.
Historical volatility
GILD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 40.2% |
| FY2023 | 32.6% |
| FY2024 | 36.9% |
| FY2025 | 39.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $29.4B |
| Cost of revenueCost Of Revenue | $6.2B |
| Gross profitGross Profit | $23.2B |
| Operating expensesOperating Expense | $11.5B |
| Research and developmentResearch And Development | $5.8B |
| Selling, general and administrativeSelling General And Administration | $5.7B |
| Total expensesTotal Expenses | $17.7B |
| Operating incomeOperating Income | $11.7B |
| Interest and other | |
| Pretax incomePretax Income | $9.8B |
| TaxTax Provision | $1.3B |
| Net incomeNet Income | $8.5B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $59.0B |
| Current assetsCurrent Assets | $18.3B |
| Non-current assetsTotal Non Current Assets | $40.7B |
| LiabilitiesTotal Liabilities Net Minority Interest | $36.4B |
| Current liabilitiesCurrent Liabilities | $11.8B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $24.6B |
| EquityTotal Equity Gross Minority Interest | $22.6B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $10.0B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $10.0B |
| Net income, continuing operationsNet Income From Continuing Operations | $8.5B |
| Depreciation and amortisationDepreciation And Amortization | $2.8B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.8B |
| Depreciation | $370.0M |
| Amortization cash flowAmortization Cash Flow | $2.4B |
| Amortization of intangiblesAmortization Of Intangibles | $2.4B |
| Stock-based compensationStock Based Compensation | $894.0M |
| Deferred taxDeferred Tax | $160.0M |
| Deferred income taxDeferred Income Tax | $160.0M |
| Operating gains and lossesOperating Gains Losses | -$451.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$451.0M |
| Asset impairmentAsset Impairment Charge | $590.0M |
| Change in working capitalChange In Working Capital | -$3.9B |
| Other non-cash itemsOther Non Cash Items | $1.5B |
| Investing cash flowInvesting Cash Flow | -$4.8B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$4.8B |
| Capital expenditureCapital Expenditure | -$563.0M |
| Capital expenditure (reported)Capital Expenditure Reported | — |
| Purchase of PP&EPurchase Of PPE | -$563.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$563.0M |
| AcquisitionsPurchase Of Business | -$1.1B |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$1.1B |
| Purchase of investmentsPurchase Of Investment | -$4.1B |
| Sale of investmentsSale Of Investment | $909.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$3.2B |
| Other investing changesNet Other Investing Changes | $3.0M |
| Financing cash flowFinancing Cash Flow | -$7.7B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$7.7B |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$1.8B |
| Net debt issuedNet Issuance Payments Of Debt | -$1.8B |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$1.8B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$1.8B |
| Shares issuedIssuance Of Capital Stock | $408.0M |
| Common stock issuedCommon Stock Issuance | $408.0M |
| Net common stock issuedNet Common Stock Issuance | -$1.5B |
| Common stock repurchasedCommon Stock Payments | -$1.9B |
| Share buybacksRepurchase Of Capital Stock | -$1.9B |
| Dividends paidCash Dividends Paid | -$4.0B |
| Common dividends paidCommon Stock Dividend Paid | -$4.0B |
| Other financing chargesNet Other Financing Charges | -$440.0M |
| Change in cashChanges In Cash | -$2.5B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 9,200.0% |
| Cash at the start of the yearBeginning Cash Position | $10.0B |
| Cash at the end of the yearEnd Cash Position | $7.6B |
| Free cash flowFree Cash Flow | $9.5B |
| Supplemental |
Learn while you research
Academy chapters picked for Gilead Sciences, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read